On October 17, FiercePharma released the top 10 vaccine companies in the world.
has had several happy and sad companies. The outbreak of COVID-19 not only stabilized the top position of Pfizer and added several new high-ranking companies, but also shook GSK, Sanofi , Merck and other long-term backbone positions in the vaccine field.
Since the COVID-19 pandemic, Pfizer/BioNTech's new crown vaccine Comirnaty has been ranked first. Before the COVID-19 pandemic, Pfizer's vaccine business was mainly the pneumonia vaccine Prevnar 13. The product's sales in 2019 were US$5.85 billion, accounting for 89% of the total revenue of the vaccine business; although the sales of the Prevnar series of products in 2021 were US$5.27 billion, it was far less than the US$36.8 billion revenue brought by Comirnaty.
Other Pfizer vaccines, such as the B meningitis vaccine Trumenba, also generated $118 million in revenue in 2021. In August this year, Pfizer released positive clinical data on phase III of respiratory syncytial virus (RSV) vaccine, and will compete with strong competitors such as GSK, , Johnson & Johnson . Analysts predict that Pfizer's RSV vaccine will contribute $2.1 billion in revenue by the end of 2030.
It is worth noting that there are 2 Chinese companies on this list, China Sinovac and Zhifei Bio .
Thanks to the huge revenue brought by the new crown vaccine, China's Sinovac sales increased nearly three times in 2021, surpassing Moderna and ranking among the top three. The new crown vaccine CoronaVac is the main driving force. In addition, Sinovac also has vaccines for seasonal and pandemic influenza, polio, , hepatitis A, hepatitis B, pneumococcal and other vaccines.
Zhifei Bio is the most well-known identity or a Chinese agent of Merck's HPV vaccine Gardasil/Gardasil 9. At present, HPV vaccine has become the cornerstone of Zhifei Bio's business. Before reaching an agreement with Merck in 2018, Zhifei Bio's revenue was about 700 million yuan, and soared to 15.2 billion yuan in 2020.
The Gardasil 9 agent of Zhifei Bio was nearly 10.2 million doses in China, and the increase of nearly four times in 2022H1 to about 9.3 million doses. In August this year, the China Medical Products Administration approved the expansion of Gardasil 9's applicable population to women aged 9 to 45, which is expected to further increase the number. In addition to HPV, Zhifei Bio has also cooperated with Merck to cooperate with a number of vaccines, including rotavirus vaccine RotaTeq, pneumococcal polysaccharide vaccine Pneumovax 23 and hepatitis A vaccine Vaqta.
Moderna's new crown vaccine Spikevax and Pfizer/BioNTech's new crown vaccine Comirnaty have always been in a competitor relationship, and they are chasing each other. In August 2022, Moderna also sued Pfizer/BioNTech for infringement of the new crown vaccine, believing that the latter "plagiarized" its breakthrough technology. In addition, Moderna's product pipeline also includes vaccines for influenza , RSV, HIV virus , shingles virus, Zika virus , Nipa virus and other vaccines.
The core product of Merck's vaccine revenue is the HPV vaccine Gardasil/Gardasil 9. Sales in 2021 reached US$5.7 billion, a significant increase from US$3.9 billion during the 2020 pandemic. Thanks to strong growth in the Chinese market, Gardasil/Gardasil 9 continued to flourish in 2022H1, achieving revenue of US$3.1 billion.
Merck also has a series of blockbuster vaccines, including ProQuad for preventing measles , mumps , rubella and chickenpox , and Varivax, which is only used to prevent varicella, earning a total of US$2.1 billion in 2021. The company's RotaTeq vaccine for preventing young children's rotavirus continued to climb steadily, reaching US$807 million in 2021.
GSK vaccine includes shingles, meningitis, influenza, hepatitis, etc. Shingrix is the most important product in the GSK vaccine field. Sales in 2022H1 have more than doubled to £1.429 billion, mainly due to factors such as the recovery of demand in Europe and the United States and the strong commercial execution of the shingles vaccine vaccination time.
Although Sanofi does not have the support of the new crown vaccine, it has always been at the world's leading level in flu vaccines, and still brought about $3.1 billion in sales in 2021. At the same time, Sanofi has several other products, including polio, whooping cough , B type Haemophilus influenzae and meningitis vaccine.
AstraZeneca 's Vaxzevria is also one of the first batch of COVID-19 vaccines recognized by regulators, but due to factors such as reduced effectiveness, delayed delivery, and thrombosis safety issues, market development is very difficult.
At the end of February 2021, Johnson & Johnson's new crown vaccine was also approved by the FDA. Although its development momentum has also declined due to issues such as effectiveness and thrombosis safety, it brought about $1 billion in revenue in the first half of this year.
This article is from the Medical Rubik's Cube
